OPA1 and atherosclerosis: At present, AMPK–YAP–OPA1 pathway has been reported in the treatment of renal ischemia–reperfusion injury, cerebral ischemia–reperfusion injury, cardiac reperfusion stress and other diseases, but there is no report on the treatment of atherosclerosis (Deng et al., 2016; Wang et al., 2016; Sun et al., 2017; Zhang et al., 2019).